Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus placebo crossover study in moderate to severe COPD
2013-001477-25Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Peak inspiratory capacity after 21 days. Started Oct 2013; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-001477-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001477-25.